<!DOCTYPE html>
<html>
  <head>
      <meta charset="utf-8">
      <meta http-equiv="x-ua-compatible" content="ie=edge">
      <meta name="description" content="">
      <meta name="viewport" content="width=device-width, initial-scale=1">
      <script type='text/javascript'>if(console){console.error('Failed to load page metadata.')}</script>
      <title>Merck Is Finding PD-L1 Testing Is Helping Keytruda</title>
      <link rel="icon" type="image/png" href="/dist/img/favicon.png" />
      <link href='https://fonts.googleapis.com/css?family=PT+Serif:400,400italic|Roboto:400,300,500,700,400italic|Roboto+Condensed:400,700,700italic' rel='stylesheet' type='text/css'>
   </head>
   <body>
   <div class="main-content-pdf" id="mainContentPdf" style="padding:0 60px;">
    <div class="pdf-header">
		<div class="pdf-logo" style="float:left;">
			<a href="/"><img src="../dist/img/logo.png" /></a>
		</div>
		<div style="float:right;">
			<div style="clear:both;">26 September 2016</div>
			<div style="clear:both;"><a href="#" style="color:#9E310D;">https://scrip.pharmamedtechbi.com</a></div>
		</div>
	</div>
	<hr/ style="clear: both;">
    <div class="pdf-body" style="clear:both;">
		<table>
		<tr><td><h1 style="font-size: 47px; line-height: 55px; margin-bottom:0;">Briefing title goes here </h1></td></tr>
		<tr><td><p style="font-size: 24px; line-height: 35px; margin-top:0;">Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque commodo justo nec sagittis ultricies.
		Aliquam aliquet dolor eu vestibulum fermentum. Fusce tincidunt elementum elit at ornare.</p></td></tr>
		<tr style="clear: both;">
				<td style="float: left; font-size: 24px; line-height: 30px; border-right:1px solid #d1d3d4; padding:0 10px 0 0; font-weight: 700;">26 Sept 2016</td>
				<td style="float: left; font-size: 24px; line-height: 30px;  border-right:1px solid #d1d3d4; padding:0 10px 0 10px; font-weight: 700;"><strong>NEWS</strong></td>
				<td style="float: left; font-size: 24px; line-height: 30px;  border-right:1px solid #d1d3d4; padding:0 10px 0 10px; font-weight: 700;"><font color="#be1e2d">Regulation</font></td>
				<td style="float: left; font-size: 24px; line-height: 30px;  border-right:1px solid #d1d3d4; padding:0 10px 0 10px; font-weight: 700;"><font color="#be1e2d">Product Safety</font></td>
				<td style="float: left; font-size: 24px; line-height: 30px;  padding:0 10px 0 10px; font-weight: 700;"><font color="#be1e2d">South Korea</font></td>
		</tr>
		<tr><td><hr/ style="clear:both; width:190px; color: #000; margin: 30px 0;"></td></tr>
		<tr><td><h1 style="font-size: 47px; line-height: 55px; margin-top:0;  ">PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing</h1></td></tr>
		<tr><td><p style="font-size: 24px; line-height: 30px; font-weight: 700; margin-top:0; margin-bottom:0; ">by Brenda Sandburg</p></td></tr>
		<tr>
				<td style="color:#be1e2d; padding:0 10px 0 0; border-right:1px solid #d1d3d4; float:left; font-size: 24px; line-height: 30px;font-weight: 700; ">@brendasandburg</td>
				<td style="color:#be1e2d;  padding:0 10px 0 10px; float:left; font-size: 24px; line-height: 30px; font-weight: 700;">Brenda.Sandburg@informa.com</td>
		</tr>
		<tr><td><hr/ style="clear:both; width:190px; color: #000; margin: 30px 0;"></td></tr>
		<tr><td><h3 style="font-size: 35px; line-height: 45px; margin-bottom:0; margin-top:0;">Executive Summary</h3></td></tr>
		<tr><td><p style="font-size: 24px; line-height: 35px;  margin-top:0;">Spanish company PharmaMar has filed for approval of its anticancer Aplidin in the EU, which if successful would be its second product to reach the market.</p></td></tr>
		<!--starting of Image-->
		<tr><td>
			<div style="float:left; margin-right:40px;">
				<img src="../dist/img/SC1609_AplidiumAlbicans_1200x675.jpg"/>
				<div style="margin-top:15px;">
					<span style="text-transform:uppercase; float:left;">THIS IS AN IMAGE CAPTION</span>
					<span style="font-style:italic; float:right;">Source:PharmaMar</span>
				</div>
			</div>
			<div style="font-size: 24px; line-height: 35px;">
				<p style="margin-top:0; margin-left: 30px; margin-right: 30px;"><font color="#be1e2d"><strong>PharmaMar SA</strong> </font>has filed for EU approval of its marine-derived anticancer agent Aplidin (plitidepsin) for use in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.</p>
				<p style="margin-top:0;">The filing, which appears to be the product’s first, is based on data from the Phase III ADMYRE study, top- line data from which were releasedin March. This showed a significant 35% reduction in the risk of progression or death over dexamethasone alone, meeting its primary endpoint (p=0.0054). The trial enrolled more than 250 patients in the US, Europe and Asia Pacific who had relapsed or refractory disease following a minimum of three and no more than six prior therapeutic regimens.</p>
				<p style="margin-top:0;">At the time, analysts from <font color="#be1e2d"><strong>Informa Pharma’s Biomedtracker PharmaMar SA</strong></font> has filed for EU approval of its marine-derived anticancer agent Aplidin (plitidepsin) for use in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma.</p>
				<p style="margin-top:0;">The filing, which appears to be the product’s first, is based on data from the Phase III ADMYRE study, top-line data from which were released in March. This showed a significant 35% reduction in the risk of progression or death over dexamethasone alone, meeting its primary endpoint (p=0.0054). The trial enrolled more than 250 patients in the US, Europe and Asia Pacific who had relapsed or refractory disease following a minimum of three and no more than six prior therapeutic regimens.</p>
				<div>
				<div style="float: left; width: 600px;">
				<p style="margin-top:0;">At the time, analysts from <font color="#be1e2d"><strong>Informa Pharma’s Biomedtracker </strong></font> commented that the positive results were “encouraging news for Aplidin”. They continued: “In Phase II studies, Aplidin showed only weak signs of efficacy as monotherapy for multiple myeloma. However, there was evidence of improved efficacy in combination with dexamethasone. This larger Phase III trial has confirmed the efficacy of the Aplidin dexamethasone combination.”</p>
				</div>
				<div style="background-color: #fff2f4; width: 400px;  float: right; padding: 30px 50px;">
					<p style="font-size:25px; line-height:35px; font-weight:700;"> Market Access & Reimbursement: Inside The Payer Perspective On Multiple Myeloma</p>
					<p style="font-style: italic; font-size: 20px; line-height: 30px;">For more information, check out the recent complimentary <font color="#be1e2d">webinar</font>from Informa Pharma Intelligence’s Datamonitor Healthcare and the reimbursement consultants at RealEndpoints.</p>
				</div>
				</div>
				<tr><td><h3 style="font-size: 35px; line-height: 45px; margin-bottom:0; margin-top:0;">Novel Mechanism</h3></td></tr>
		<tr><td><p style="font-size: 24px; line-height: 35px;  margin-top:0;">Plitidepsin was originally obtained from the ascidian (sea squirt) Aplidium albicans. PharmaMar says it specifically binds to the eEF1A2 protein, resulting in tumor cell death via apoptosis. Having a novel mechanism of action should stand the drug in good stead given the increasing number of products entering the market for multiple myeloma.</p></td></tr>
		<tr><td><p style="font-size: 24px; line-height: 35px;  margin-top:0;">Guidelines from the National Comprehensive Cancer Network advise regimens including Velcade, Revlimid or its predecessor Thalomid for first-line therapy, though other brands are trying to break in to that line of treatment. Newer drugs are included for use in the second-line or greater, as patients relapse repeatedly
(see graphic).</p></td></tr>
		<!--starting of Dashboard-->
		<tr><td>
		<!--starting of Dashboard div-->
		<div style="float: right; width:500px;">
			<img src="../dist/img/SC1609_MMTreatmentPathway.gif" width="500px"/>
				<div style="margin-top:15px;">
					<p style="font-size: 18px; line-height: 30px; margin-top:0;">Source: NCCN, Informa</p>
					<p style="font-size: 18px; line-height: 30px; margin:0;">This is available as an interactive dashboard / video.</p>
					<p style="font-size: 18px; line-height: 30px; margin:0;"><font color="#be1e2d">Click here.</font></p>
				</div>
		</div>	
		<div style="font-size: 24px; line-height: 35px; ">
			<p style="margin-top: 0;">
			Head-to-head trials represent one way of influencing payers from removing agents from coverage, said Beth Nash, chief medical officer at the reimbursement intelligence company RealEndpoints, in the webinar.			
			</p>
			<p>With Velcade generics on the horizon, Amgen has taken on that challenge and tested Kyprolis head-tohead against Velcade. The strategy was successful in the second-line ENDEAVOR study, in which Kyprolis was associated with a significant progression-free
survival benefit over Velcade. But the firm suffered a setback with the failure of the first-line CLARION study, which tested Kyprolis with melphalan and prednisone against Velcade and the same background regimen in newly-diagnosed patients. Amgen argues that the
particular regimen used in the study is not used very much anymore and that results from the first-line, head-to-head ENDURANCE study, which is sponsored by the National Cancer Institute, are still pending (Also see “Amgen’s Kyprolis Miss In First-Line Myeloma
Surprising, But Clinically Irrelevant” - Scrip, 27 Sep, 2016.)
			</p>
			<p>The filing, which appears to be the product’s first, is based on data from the Phase III ADMYRE study,
top-line data from which were released in March. This showed a significant 35% reduction in the risk of progression or death over dexamethasone alone, meeting its primary endpoint (p=0.0054). The trial enrolled more than 250 patients in the US, Europe and Asia Pacific who had relapsed or refractory disease following a minimum of three and no more than six prior therapeutic regimens.</p>
		</div>
		<tr><td><hr/ style="clear:both; width:190px; color: #000; margin: 30px 0;"></td></tr>
		<tr><td><h3 style="font-size: 35px; line-height: 45px; margin-bottom:0; margin-top:0;">Related Content</h3></td></tr>
		<tr><td></tr></td>
		<tr><td><hr/ style="clear:both; width:190px; color: #000; margin: 30px 0;"></td></tr>
		
		</td></tr>
		<!--End of Dashboard-->
		</div>
		<!--End of Dashboard div-->
		</tr></td>
		<!--End of Image-->		
		</table>
		
	</div>
	<hr/ style="clear:both;">
    <div class="pdf-footer">
		<table>
			<tr><td  style="font-size:18px; line-height:30px; border-right:1px solid #000; font-weight: 700; padding: 0 10px 0 0;">© Copyright: Agribusiness Intelligence</td>
				<td style="font-size:18px; line-height:30px; border-right:1px solid #000; padding: 0 10px;"> Generated by [User] </td>
				<td style="font-size:18px; line-height:30px; border-right:1px solid #000; padding: 0 10px;"> 26 Sep 2016</td></tr>
			<tr><td colspan="4"style="font-size:18px; line-height:30px; clear: both;">Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors</td></tr>
		</table>
	</div>
	<hr/ style="clear:both;">
	</div>
	</body>
</html>	
